Background: Prevalence is a statistic of primary interest in public health. In the absence of good followup facilities, it is difficult to assess the complete prevalence of cancer for a given registry area. Objective: An attempt was here made to arrive at complete prevalence including limited duration prevalence with respect to selected sites of cancer for India by fitting appropriate models to 1, 3 and 5 years cancer survival data available for selected population-based registries. Materials and Methods: Survival data, available for the registries of Bhopal, Chennai, Karunagappally, and Mumbai was pooled to generate survival for breast, cervix, ovary, lung, stomach and mouth cancers. With the available data on survival for 1, 3 and 5 years, a model was fitted and the survival curve was extended beyond 5 years (up to 35 years) for each of the selected sites. This helped in generation of survival proportions by single year and thereby survival of cancer cases. With the help of survival proportions available year-wise and the incidence, prevalence figures were arrived for selected cancer sites and for selected periods. Results: The prevalence to incidence ratio (PI ratio) stabilized after a certain duration for all the cancer sites showing that from the knowledge of incidence, the prevalence can be calculated. 
Introduction
Prevalence is a statistic of primary interest in public health because it identifies the level of burden of disease or health-related events on the population and health care system. Prevalence represents new and pre-existing cases alive on a certain date, in contrast to incidence which reflects new cases of a condition diagnosed during a given period of time. Prevalence is a function of both the incidence of the disease and survival. The prevalence for cancer is calculated in two major ways: Tumor based and person based. Whenever the interest of investigator lies in finding out the prevalence of certain tumor like breast cancer, cancer of cervix or lung cancer then actually the tumor based prevalence is calculated. But, when the interest is to find out the number of person suffering from cancer regardless of the tumor from which they are suffering then the calculation of person based prevalence is required.
Cancer is still a relatively a rare disease in India (incidence≈0.1%) and no good follow-up facilities are available, at present, with many of the Indian cancer registries. The complete survival data of cancer cases can be of great help in this regard. But, the survival data which is available with our country is only for a limited duration (1 year, 3 years and 5 years) and that too for selected cancer sites only which at most may facilitate estimating of cancer cases for limited duration only. Estimation of prevalence for complete duration for various cancer sites including all-sites cancer still remains a challenge. An attempt is therefore made to develop a model approach to estimate the prevalence of cancer cases using Indian cancer Incidence and limited survival data.
The objectives of the present study were: i) Using the available cancer survival data of 1 year, 3 years and 5 years for selected cancer sites including all-sites of cancer, to identify a best fit model for each site; ii) The best fit model equation to be used to extend the cancer survival curve beyond 5 years say up to 30 years or till such period that survival becomes zero; iii) From the extended survival curve, to generate the proportion of survivals by single years say for 1-30 years duration; iv) The survival proportions as obtained above by single years are helpful in determining the limited duration prevalence or complete prevalence; v) To show the validity of extending survival curve beyond 5 years with the help of a live data; and vi) To calculate the prevalence of cancer cases for selected cancer sites using the results of the study.
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Materials and Methods
The prevalence is calculated in two major ways: i) Tumor based; and ii) Person based. In Tumor Based Cancer, an attempt is made to find out the number of primary cancers diagnosed among individuals living on a specified date while in Person Based Cancer, an attempt is made to find out the number of individuals living with cancer on a specified date. Since the personbased approach counts the number of individuals with cancer rather than the number of diagnosed tumors, it can underestimate the true burden of cancer. The person based prevalence is again categorized in two ways: i) Complete prevalence; and ii) Limited duration prevalence. The Complete Prevalence represents the proportion of people alive on a certain day who previously had a diagnosis of the disease, regardless of how long ago the diagnosis was, or if the patient is still under treatment or is considered cured. The registries with long duration of working (more than 30 years) and good follow-up facilities could only give the complete prevalence. The registries with short duration of working say 15-20 years can at-most provide the information on Limited Duration Prevalence. It represents the proportion of people alive on a certain day who had a diagnosis of the disease, within the past 'X' years. Prevalence can be examined over various durations of time say 5 years, 10 years or 15 years.
In a Scientific Report (N0. 162) of IARC, the registries of Bhopal, Chennai, Karunagappally and Mumbai provided their survival rates for three selected periods (1, 3 and 5 years) and for 16, 20, 22 and 28 sites, respectively. Three sites each were identified for males (Stomach, Lung and Mouth) and females (Breast, Cervix and Ovary) separately. In addition, cancer as a whole (All-sites) is also considered. The survival data was pooled separately for each selected site by periods for all the registries. Using the pooled-survival data of 1 year, 3 years and 5 years of selected cancer sites an attempt was made to identify a best fit model to describe the 1 year, 3 years and 5 years survival data. Then the best fit model equation was utilized to extend the survival curve beyond 5 years say up to 30 years or till such period that the survival becomes zero. From the extended survival curve, the proportion of survivals by single years say for 1-30 years duration is determined. The survival proportions so obtained by single years in combination with the knowledge of prevailing incidence rates of cancers are helpful in determining the life time prevalence or complete prevalence.
For calculation of prevalence, for the selected cancer site, it is assumed that the cancer incidence rate for the registry remains constant over the years and the incidence cases of the registry are 100,000 for the base year 2001. Further, the incidence cases are expected to grow proportionately to the population growth rate (16.34% decadal growth rate). Then, applying the survival proportions and the incidence estimates for the years say 2001-2030, the prevalence figures are estimated. The prevalence to incidence ratio is also calculated for each single year till such time that it almost become constant. Such a P/I ratio is termed as stabilized P/I ratio. Then stabilized P/I ratio can be utilized to multiply the latest incidence cases to arrive at the point prevalence.
An attempt is also made to predict prevalence cases of selected cancer sites, utilizing the published data of incidence cases at India level for selected cancer sites and for selected periods (Takiar et al., 2009) .
There are two points in the model approach which needs to be highlighted. First, it looks like a simulation technique used for calculation of prevalence. Second, the use of survival equation to estimate the survival proportions outside the actual range ie., beyond 5 years. It is therefore desirable to show that the model fitted in such a way is good and can be used to derive the prevalence of cancer for any given cancer site. To prove the point, it is essential that the model approach is to be applied to a long term follow up data of a certain cancer site and then its validity to be established. Fortunately, 18 years follow up data on incidence and mortality of cervix cancer was available from Barshi cancer registry. From the incidence and mortality data, the actual survival data will be generated for the period 1988-2006 and thus the actual prevalence cases will be determined for each single year. Then, using the first five year survival data and best fitted model equation a survival curve will be generated for the period 1988-2006 and prevalence will be determined for the entire period by single years and will be compared with that of actual prevalence at each point. A non-significant chi-square, derived from actual and fitted values, will prove that the model fitted is good and can be used to predict survival and thereby prevalence for the desired period.
Results
The absolute percentage survival by different years and by different cancer registries is provided in Table  1 . The survival for 1 year varied between 55.2% in the registry of Mumbai to 62.3% in the registry of Bhopal. The 3 years survival did not show much variation between the registries (34.0-36.1%). However, the 5 years survival varied between 25.4% in Karunagappally to 28.1% in the registry of Mumbai. The pooled absolute % survival was observed to be 55.5%, 35.4% and 27.8% for the duration of 1 year, 3 years and 5 years, respectively. With the help of SPSS, a suitable curve was fitted and shown in Figure  1 . The type of equation and the respective constants are also shown in Figure. The equation is termed as the best fit equation. It can be seen that the observed and fitted values are quite close to each other suggesting the fit is good.
With the help of the best fit equation, the survival proportions are estimated for 1 year to 26 years and shown in Table 2 . The estimated survival proportion is 0.553 for first year, 0.432 for second year, 0.362 for third year and so on. The survival proportion became zero for the year 24.
An approach used for calculation of prevalence is shown in In Table 3 Table 4 .
The prevalence (P) to incidence (I) ratio calculated for 2001-2024 for India is shown separately in Table 5 . The ratio appears to stabilizing to 3.42 after the year 2022.
Based on the follow-up data of Barshi registry on the incidence and mortality cases of cervix for the period 1988-2006, the prevalence figures were calculated for each year and shown in second and sixth columns (Table 6) . Following the survival of 1 year, 3 years and 5 years from the above data, as described earlier, a survival curve was generated and estimated prevalence figures were arrived for selected years and shown in third and seventh columns. The actual and estimated prevalence figures showed no significant variation from each other. The overall nonsignificant chi-square value suggests that the fit is good.
The actual and fitted prevalence figures are also shown in Figure 2 .
The percentage absolute survival of selected cancer sites, pooled for all selected cancer registries, is shown for 1 year, 3 years and 5 years period in Table 7 . The 5 years pooled survival for the cancer sites of Breast, Cervix, Ovary, Lung, Stomach and Mouth was 41.6%, 43,7%, 23.6%, 7.0%, 8.2%, 31.4% respectively.
Following the procedure described earlier, the incidence and prevalence figures were generated for selected cancer sites with the help of suitable survival curves and prevalence to Incidence ratios are calculated for different years but shown for years which are multiple of five (5, 10, 15, 20, 25, 30, 35) in Table 8 . The P/I ratio for the cancer sites of breast, cervix, ovary, stomach, lung and mouth for 5 years duration was 2.87, 2.89, 1.84, 0.77, 0.69 and 2.12 respectively. Similarly, the respective life time figures for above sites were 4.90, 5.33, 2.75, 1.40, 1.37 and 4.04 respectively. For All sites, the ratio for 5 year, 10 years, 15 years and life time was 1.88, 2.75, 3.19 and 3.42, respectively.
Considering the above stabilized P/I ratios for selected cancer sites and with the knowledge of cancer incidence cases for India, the prevalent cancer cases are calculated for India for selected three periods and shown in Table 9 . In India, by the year 2020, the prevalent cancer cases of breast, cervix and ovary are estimated to be 605.1, 657.1 90, 659 106, 124 123, 634 4.90 444, 229 520, 008 605, 807 Cervix 103, 821 113, 138 123, 291 5.33 553, 366 603, 026 657, 141 Ovary etc. 30, 482 33, 218 36, 199 2.75 83, 826 91, 350 99, 547 Males Lung 44, 301 47, 622 51, 193 1.40 62, 021 66, 671 71, 670 Stomach 25, 831 27, 767 29, 850 1.37 35, 388 38, 041 40, 895 Mouth 30, 920 38, 380 46, 784 4.04 124, 917 155, 055 189, 007 All sites** 979,787 1, 060,889 1,148,758 3.42 3,350,872 3,628,240 3,928,752 *Takiar R et al. (2010) and 99.5 thousand respectively. Similarly, the prevalent cancer cases of lung, stomach and mouth among males by the year 2020 will be 71.7, 40.9 and 189.0 thousand respectively. By the year 2020, the overall prevalent cancer cases in India are estimated to be rising to 3.9 millions.
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Discussion
Prevalence of cancer is a statistic of primary interest in public health. It identifies the level of burden of cancer on the population and health care system. It is taken as a function of both the incidence of the disease and survival. In India, while reasonably good incidence data is available, still mortality data is far from being reliable and satisfactory. The variation seen in MI ratio of various Indian registries further substantiates this fact: NCRP, (2010). In the absence of good follow up facilities at the registry level, the correct assessment of prevalence of cancer is a distant dream.
The use of models in assessment of different diseases under different conditions is well documented (Merrill et al., 2000; Kruijshaar et al., 2002; Kruijshaar et al., 2003; Nacul et al., 2007) . Incidence-prevalence-mortality (IPM) models have been used for improving estimates of disease epidemiology. The discrepancies between model estimates and observations are sometimes caused both by the data inaccuracies and change in the trends of incidence or mortality Kruijshaar et al. (2002) . In SEER data, also, models are used to estimate the Cancer prevalence Merrill et al. (2000) . Disease models describing the relationship between incidence, prevalence and mortality are also used to detect data problems or to supplement missing data Kruijshaar et al. (2003) . The model can be used to estimate population prevalence of COPD from large general practices to national level, and as a tool to identify areas of high levels of unmet needs for COPD priority health actions Nacul et al. (2007) . A robust and well-researched disease prevalence model can help Health Planners to assess the true needs of their community, calculate the level of services needed and invest the appropriate level of resources for prevention, early detection, treatment and care.
The model approach used in the paper allow us to estimate the prevalence for different cancer sites and for different time periods say for multiples of 5 years like 5, 10, 15, 20, 25, 30 and 35 years. The exercise carried out in the present paper further showed that for all the cancer sites, a year comes in a period (up to 35 years) when prevalence to incidence ratio become constant or do not show appreciable changes. The fact that PI ratio becomes almost constant or stabilizes after certain duration for all the cancer sites shows that from the knowledge of incidence, the prevalence can be calculated. The stabilized P/I ratio for the cancer sites of breast, cervix, ovary, stomach, lung and mouth for life time was observed to be 4.90, 5.33, 2.75, 1.40, 1.37 and 4.04 respectively. The variation in PI ratio by different sites is logical as they have different survival rates. The higher the survival rate, the higher the PI ratio. Since, the stomach and lung cancer are known to have low survival rates so their PI ratios are also shown to be lower as compared to other sites.
The exercise based on Barshi cervix data proved the following points beyond doubt that: i) From the best fit survival curve to 1, 3 and 5 years survival data, the curve can be extended beyond 5 years; ii) From the survival curve, the survival proportions can be decided for each single year between 1-18 years; iii) In combination of knowledge of incidence and mortality the prevalence figures can be calculated for each single year; iv) The model generated prevalence figures beyond 5 years and for life time were found to be comparable with actual prevalence figures; v) The model approach used in the present paper is validated for its prediction power, adequately with the support of actual data. Since the requirement of the model approach to estimate the prevalence figures for limited duration as well as for life time prevalence is only the knowledge of continuous incidence data and five year survival data, the approach will be cost-effective.
Realizing the fact that most of the Indian cancer registries are able to generate good incidence data but however are not having good follow up facilities, we advocate the use of PI ratio values provided by us to be used for generating of prevalence figures at their registry levels. Further the approach advocated in the present paper can be replicated anywhere in the world with the knowledge of current incidence, population figures and 1-5 years survival data to generate prevalence figures for their country level or at registry level.
In conclusion, the validity of the model approach to calculate prevalence is demonstrated with the help of survival data of Barshi registry for Cervix cancer, available for the period 1988-2006. Given the incidence of cancer at India level or at the registry level, the overall prevalence can be obtained simply by multiplying the incidence by a factor of 3.42. Similarly, for the cancer of breast, cervix and ovary, the multiplying factor to get lifetime prevalence from the knowledge of incidence will be 4.9, 5.33 and 2.75, respectively. In the case of males, for the cancer of lung, mouth and stomach, the multiplying factor will be 1.4, 1.37 and 4.04, respectively.
